ReviewFrontiers in medicine2026
Flumazenil reversal of remimazolam-induced sedation: a narrative review of safety, pharmacokinetics, and clinical considerations.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal Dosing Strategies for Remimazolam Across Diverse Patient Populations: A Clinical Narrative Review.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Remimazolam, an ultra-short-acting benzodiazepine metabolized by carboxylesterase-1 (CES1), permits specific antagonism by flumazenil, enabling active reversal unavailable with propofol-based sedation. However, the safety profile of this reversal strategy-including re-sedation risk, seizure concerns, and special population considerations-remains incompletely characterized. Methods: This narrative review synthesizes evidence from randomized controlled trials, meta-analyses, pharmacokinetic-pharmacodynamic modeling studies, and pharmacogenomic research identified through comprehensive searches of PubMed, Embase, the Cochrane Library, and Google Scholar through February 2026 to evaluate the clinical utility and safety considerations of flumazenil reversal in remimazolam-based anesthesia. Results: Recent meta-analyses demonstrate that remimazolam-flumazenil accelerates emergence by approximately 4 min versus propofol with significant reductions in respiratory depression (RR 0.41; 95% CI 0.30-0.56) and hypotension (RR 0.25; 95% CI 0.12-0.52), though substantial heterogeneity ( Discussion: This review identifies critical evidence gaps-including the need for standardized re-sedation definitions, prospective validation of pharmacokinetic-pharmacodynamic models, and pediatric pharmacokinetic data-and provides evidence-based considerations for clinical practice while emphasizing the need for systematic review methodology and expert consensus to develop formal clinical guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.